Suppression-and-Replacement (SupRep) Therapy
Definition
Suppression-and-replacement (SupRep) therapy is a hybrid gene therapy strategy that simultaneously silences endogenous gene expression (via shRNA targeting both wild-type and mutant transcripts) while reintroducing a functional, knockdown-resistant wild-type transgene. It addresses the limitations of allele-specific targeting in diseases with extreme mutational heterogeneity.
Key Concepts
- Why SupRep is needed: In LQTS caused by KCNQ1 or KCNH2 mutations, hundreds of rare disease-causing variants exist with no single predominant mutation. Allele-specific RNAi must be redesigned for each variant, making it clinically impractical. SupRep is mutation-agnostic. (sources/gene-therapy-arrhythmia-2025)
- Mechanism: shRNA suppresses endogenous transcripts (both wild-type and mutant); a shRNA-immune engineered cDNA restores protein function. Both components are typically co-delivered via AAV9. (sources/gene-therapy-arrhythmia-2025)
- LQT1 (KCNQ1) results: AAV9-SupRep normalized QTi and APD90 in transgenic LQT1 rabbits; restored physiological β-adrenergic QT shortening; reduced QT dispersion. No inflammation or adverse events (Bains 2024; Dotzler 2023). (sources/gene-therapy-arrhythmia-2025)
- LQT2 (KCNH2) results: AAV9-SupRep normalized QTc (470 → 414 ms in rabbits); suppressed early afterdepolarizations and TdP inducibility (Bains 2023). (sources/gene-therapy-arrhythmia-2025)
- SQTS1 (gain-of-function KCNH2 N588K): shRNA-only silencing (no replacement needed for gain-of-function) prolonged QTc from 283 to 333 ms; reduced TdP inducibility (5/7 → 1/8 animals). (sources/gene-therapy-arrhythmia-2025)
- SupRep has also been applied to: hiPSC-CM models of LQT2, SQTS1, and calmodulin-associated LQTS — demonstrating versatility across multiple channelopathy genotypes. (sources/gene-therapy-arrhythmia-2025)
- Critical dosing balance: Excess suppression without adequate replacement worsens the LQTS phenotype; excess replacement without suppression risks inducing a short QT phenotype. Iterative dose escalation and in silico modeling required. (sources/gene-therapy-arrhythmia-2025)
- Broader applicability: The modular, scalable approach holds potential for any monogenic cardiovascular disorder characterized by dominant-negative pathophysiology. (sources/gene-therapy-arrhythmia-2025)
- One construct, four LQT1 mutations: a Sup-Rep lentivirus encoding a KCNQ1-targeting shRNA and a shIMM KCNQ1 cDNA shortened action potentials in hiPSC-CMs carrying four different KCNQ1 pathogenic variants, and was extended to LQT2 and SQT1 cells — the clearest demonstration that a single construct can cover every variant in a gene. (sources/gene-therapy-arrhythmia-cjca-2026, rating: high)
- A single construct for all calmodulinopathies. Because CALM1, CALM2 and CALM3 encode an identical 149-amino-acid protein, one Sup-Rep therapeutic carrying three shRNAs (one per CALM gene) plus a shIMM CALM1 cDNA normalised action potential duration in hiPSC-CMs from all three CALM-LQTS subtypes (CALM1-p.F142L, CALM2-p.D130G, CALM3-p.D130G). This is the only strategy in the field that is genotype-universal across a whole gene family. (sources/gene-therapy-arrhythmia-cjca-2026)
- LQT1 rabbit — partial knockdown is enough: three weeks after aortic-root injection of AAV9-Sup-Rep, QT interval and QT dispersion normalised to wild-type at baseline and after isoproterenol, with restored physiological APD and isoproterenol response in isolated cardiomyocytes — on only ~30% reduction of mutant human KCNQ1 mRNA. (sources/gene-therapy-arrhythmia-cjca-2026)
- SQT1 rabbit: silencing 60% of the mutant transcript in the left ventricle substantially recovered QTc and apicobasal APD₉₀ heterogeneity, with IKr behaviour normalised in 47% of cells. In silico, a diffusely dispersed 1:1 ratio of affected to corrected cells more than halved arrhythmic episode duration. (sources/gene-therapy-arrhythmia-cjca-2026)
Contradictions / Open Questions
- Critical dosing balance — therapeutic window undefined in humans: Excess shRNA suppression without adequate replacement worsens the LQTS phenotype (insufficient IKs/IKr); excess replacement without suppression risks inducing a short QT phenotype. This balance has been demonstrated in animal models but the therapeutic window has never been established in humans. Phase I dose-escalation trials will need to define safe ratios before broader clinical use. (sources/gene-therapy-arrhythmia-2025)
- SupRep for SQTS1 — silencing only, no replacement: For SQTS1 (gain-of-function KCNH2), shRNA silencing alone (without replacement) is the therapeutic goal. But excessive silencing of KCNH2 in a patient whose baseline QTc is already short risks inducing LQT2. The optimal silencing dose is even more tightly constrained in this context. (sources/gene-therapy-arrhythmia-2025)
- AAV delivery limitations apply: SupRep is co-delivered via AAV9. All AAV constraints (pre-existing immunity, re-dosing restrictions, episomal dilution in pediatric patients, liver off-target) apply to SupRep. The durability of the shRNA+cDNA combination in human cardiomyocytes over decades is untested. (sources/gene-therapy-arrhythmia-2025)
- QT normalisation is not the same as arrhythmia protection. The LQT1 rabbit study that showed QT and dispersion normalisation did not comprehensively test arrhythmia susceptibility. Every efficacy claim for Sup-Rep in LQTS therefore rests on a surrogate — action potential duration, QTc, or dispersion — rather than on arrhythmia or SCD endpoints. (sources/gene-therapy-arrhythmia-cjca-2026, rating: high)
- The silencing is not confined to the heart. In the LQT1 rabbit work, the shRNA was driven by a ubiquitous U6 promoter, so KCNQ1 knockdown could occur in any tissue — and KCNQ1 is expressed in the inner ear, gut, kidney and thyroid. The authors argue that siRNAs or miRNAs expressed under cardiomyocyte-specific promoters should be demonstrated before clinical translation. (sources/gene-therapy-arrhythmia-cjca-2026)
- The stoichiometry has never been measured in a treated animal. In the LQT1 rabbit study neither the expression level of shIMM KCNQ1 nor that of endogenous rabbit KCNQ1 was precisely assessed, so the suppression-to-replacement ratio — the parameter the whole design depends on — is unknown. (sources/gene-therapy-arrhythmia-cjca-2026)
- The calmodulinopathy construct solves a problem no other gene can pose. Silencing one CALM gene is tolerable only because the other two encode an identical protein. That is a property of this gene family, not a generalisable route for other dominant-negative diseases, where suppressing both alleles of one gene does real damage. (sources/gene-therapy-arrhythmia-cjca-2026)
Connections
- Part of concepts/Gene-Therapy-in-Arrhythmia — the parent overview
- Related to concepts/AAV-Gene-Delivery
- Related to concepts/Gene-Silencing-Therapy
- Related to concepts/iPSC-Derived-Cardiomyocytes
- Related to entities/Long-QT-Syndrome
- Related to entities/Short-QT-Syndrome
- Related to entities/KCNQ1
- Related to entities/KCNH2
- Related to concepts/Calmodulinopathy — the universal three-shRNA construct
- Related to concepts/Gene-Therapy-Transduction-Threshold — why 30% silencing can be enough
- Related to entities/PLN — the clinical-stage silencing comparator